Biotechnology company 180 Life Sciences has identified a CBD analogue that will move forward in clinical development for inflammation and pain. Born out of a merger of three companies, 180 Life Sciences is focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain. A continuing collaboration since 1998 between the […]

LEXINGTON, Ky. ­­— Richmond, Virginia-based biotech company Aditxt Inc. has partnered with Lexington-based clinical diagnostic lab SphereDX to offer an advanced COVID-19 monitoring tool called AditxtScore for COVID-19. The AditxtScore for COVID-19 is a blood test that acts as a comprehensive immune response monitoring tool that tracks multiple combinations of antibodies and neutralizing antibody responses against several different antigens, according […]

Regulus Therapeutics just finished dosing patients in toxicity studies for its second-generation autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS8429. Based on FDA discussions and data from a Phase Ib trial on original ADPKD candidate RGLS4326, Regulus is shifting away from the first-generation candidate and prioritizing the newer candidate, according to a statement.